Skip to main content
. 2016 Dec 19;11(12):e0168562. doi: 10.1371/journal.pone.0168562

Fig 8. PPARγ-agonist rosiglitazone reduces CXCL2 expression in finally differentiated 3T3-L1 adipocytes.

Fig 8

3T3-L1 pre-adipocytes were differentiated in differentiation medium for 4 days or 12 days as indicated. Differentiated 3T3-L1 cells were then stimulated with cytokines (25 ng/ml IL-1β, 50 ng/ml TNFα) for 8 h in the presence of increasing concentrations of rosiglitazone (1–4 μM). CXCL2 mRNA expression was analyzed by qRT-PCR (a). CXCL2 protein release into cell culture supernatants was determined by ELISA (b). *, p < 0.05; n.s., not significant (Student’s unpaired t test) compared to cytokine-treated, but rosiglitazone-free cells. Bars indicate the mean ± S.D. obtained from four independent experiments (n = 4).